A comparison of parameters of kits for 99mTc-radiopharmaceuticals for a cerebral perfusion diagnostics
Authors:
Jiří Štěpán
Authors‘ workplace:
Klinika nukleární medicíny FN Brno a LF MU Brno
Published in:
NuklMed 2013;2:7-12
Category:
Original Article
Overview
Introduction:
[99mTc]technetium-exametazime was the first neutral lipophilic technetium compound able to pass through the blood–brain barrier. [99mTc]technetium-bicisate is another such a complex used in a clinical practice. Both radiopharmaceuticals are prepared by labeling of cold kits of various manufacturers, which differ by their parameters compared in this work.
Methods:
A comparison of kits parameters mentioned in summaries of product characteristics (SPC), a determination of a radiochemical purity (RCP), a medical consultation of an imaging capability.
Results:
Parameters of kits for [99mTc]technetium-exametazime: BRAIN-SPECT KIT, NEUROSCAN, STABILISED CERETEC, and [99mTc]technetium-bicisate: NEUROLITE are mentioned respectively: a volume of a preparation: 5 ml, 5 ml, 7 ml, 4 ml; a maximum activity: 2.22 GBq, 1 GBq, 1.11 GBq, 3.7 GBq; a possibility of a dilution: yes, yes, yes, no; a volume of a vial: 9 ml, 10 ml, 11 ml, 5 ml; a kit stability before and after the labelling: 1 y / 1 h, 1 y / 0.5 h, 1 y / 5 h, 1.5 y / 8 h; obtained RCP / a percentage content of a free pertechnetate: 87.8 ± 0.6 / 5.9 ± 1.4, 86.6 ± 2.8 / 4.0 ± 2.7, 91.6 ± 0.9 / 1.9 ± 0.4, 97.2 ± 0.7 / not determined; comparable imaging capabilities; similar approved indications.
Conclusion:
Main [99mTc]-bicisate (NEUROLITE) advantages against [99mTc]-exametazime (other kits) are the best stability, even not reached by STABILISED CERETEC, and a use of an [99mTc]eluate without any special restrictions. Nevertheless it isn't suitable for a leucocyte labelling. Among kits for [99mTc]-exametazim STABILISED CERETEC is characterized by its longer stability and BRAIN-SPECT KIT by the highest activity. A use of kits with the long stability (NEUROLITE, STABILISED CERETEC) reaching the highest RCP is advantageous by reason of the highest relative bioavailability for a brain.
Key words:
[99mTc]technetium-exametazime, [99mTc]technetium-bicisate, d,l-hexamethylpropylene amine oxime (HMPAO), L,L-ethyl cysteinate dimer (ECD), radiochemical purity, free pertechnetate
Sources
1. Neirinckx RD. Evaluation of regional cerebral blood flow with 99mTc-d,l-HMPAO and SPECT. Neurosurg Rev 1987;10:181–184
2. Banerjee S, Samuel G, Kothari K et al. On the synthesis, isolation and radiochemical studies for the preparation of in-house kit for 99mTc-meso- and d,l-HMPAO: A few additional observations. Nucl Med Biol 1999;26:327–338
3. Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of the retention mechanism of the brain perfusion imaging agent 99mTc-bicisate (99mTc-ECD). J Cereb Blood Flow Metab. 1994;14 Suppl 1:S4-11
4. IAEA (International Atomic Energy Agency). Technetium-99m Radiopharmaceuticals: Manufacture of Kits. Vienna, IAEA, 2008, 189 p, Technical reports series no. 466, ISBN 978–92–0–100408–6
5. Škop B. Mikro-verze AISLP - ČR [CD-ROM]. 2013.1 pro MS Windows. Praha, Bohuslav Škop, 1. ledna 2013, 1 CD-ROM
6. Ministerstvo zdravotnictví ČR. Český lékopis 2009, ČL 2009 – Doplněk 2010, ČL 2009 – Doplněk 2011, ČL 2009 – Doplněk 2012: elektronická verze na CD. Praha, Grada, 2012, 1 CD-ROM, ISBN 859-404-924-026-5
7. Hodgson E, ed. A textbook of modern toxikology - 3rd edition. Hoboken, New Jersey, John Wiley & Sons, Inc., 2004, 557 p, ISBN 0-471-26508-X
Labels
Nuclear medicine Radiodiagnostics RadiotherapyArticle was published in
Nuclear Medicine
2013 Issue 1
Most read in this issue
- A comparison of parameters of kits for 99mTc-radiopharmaceuticals for a cerebral perfusion diagnostics
- Polydentate ligands for modern radiopharmaceuticals containing 64Cu – review
- The long-term effectivity control of sentinel lymph node biopsy through the follow-up of complex therapy results